Email not displaying correctly? View it in your browser.

Photo of Senator Ted Kennedy, Jr..


Ted Kennedy, Jr.

Listening to You

Kennedy Calls for Action to Rein-in Pharmaceutical Prices

Many of you have called me to express your outrage at the soaring cost of pharmaceuticals and needed medicines. This year I will be re-introducing legislation that proposes a series of reforms aimed at bringing down the rising costs of prescription drug prices in Connecticut.

Biotech and pharmaceutical companies play a pivotal role in bettering our lives and in contributing to the innovation economy of our state, and they are certainly entitled to recoup their enormous investment. However, greed-fueled price hikes and excessive profiteering are endangering the health and safety of Connecticut’s citizens. Drug prices have continued to rise despite intense criticism, so now the time has come for our state to take meaningful action.

While many of the problems with pharmaceutical pricing must be addressed at the national level, there are things that Connecticut can do on its own. My bill will take a multi-faceted approach to addressing this problem, implementing a number of solutions, including:

  • Implement a cost-transparency law that requires drug companies to account for drug development, marketing, advertising and other costs;
  • Stop purchasing in silos and require the state to aggregate its drug spending from all taxpayer-funded programs, including Medicaid, public employees and retirees, and other groups, to better leverage its competitive negotiating position;
  • Direct state agencies to immediately conduct a savings analysis should Connecticut be permitted to pay the same prices for drugs that the U.S. Department of Veterans Affairs pays for its prescription drugs;
  • Consider bulk purchasing savings presented by multi-state purchasing alliances;
  • Engage a pharmaceutical benefit manager (PBM) to develop preferred drug lists, new formularies and/or generic substitutions, harnessing market forces and better pricing competition between same-category drugs. Allow citizens to avail themselves of these prices and make the PBM a fiduciary to the states;
  • Immediately authorize and direct the State Attorney General to investigate the legality of excessive price increases under Connecticut consumer law; and
  • Direct the newly-created Connecticut state drug price task force to prioritize an analysis of various other state-initiated mechanisms that would be appropriate for Connecticut to consider.

Many of these proposals will be taken up by the Insurance Committee in the coming weeks. If you are interested in submitting written testimony or coming to the Capitol to speak in person, contact the General Assembly's Insurance and Real Estate Committee. The committee can be reached by phone at 860-240-0510, and testimony can be submitted by email to

RX Costs